NewsBenzingaKyverna Therapeutics Presents Updated Results From Its Phase 1 Trial Of CD-19 Directed CAR T-Cell Therapy In Progressive Multiple Sclerosis At MS Toronto 2026 Kyverna Therapeutics Presents Updated Results From Its Phase 1 Trial Of CD-19 Directed CAR T-Cell Therapy In Progressive Multiple Sclerosis At MS Toronto 2026 Benzinga 2026.10.23 14:31 (GMT+0) Open on Benzinga Other news David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes Bernstein Maintains Market Perform on Tyson Foods, Raises Price Target to $72 Broadcom Stock Is Up Tuesday: AI Chip Diversification, Dec. 9 Earnings, Analyst Targets SharonAI Analysts Cut Their Forecasts Following Q3 Results Bernstein Downgrades PepsiCo to Underperform, Lowers Price Target to $128 If You Invested $1000 In Humana Stock 20 Years Ago, You Would Have This Much Today